Prevalence and Significance of Incidental Findings on 68 Ga-DOTA-conjugated Somatostatin Receptor-targeting Peptide PET/CT: a Systematic Review of the Literature
Overview
Affiliations
Aim: We aimed to evaluate the prevalence of incidental Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy.
Materials And Methods: Studies reporting incidental SSTR PET/CT findings were systematically searched in PubMed, Cochrane, Embase and Web of Science literature published prior to 1 of May 2020. Studies were filtered by two independent readers for eligibility based on title and abstract, and subsequently on full text. The main exclusion criteria were: 1) pathological findings that matched scan indication, 2) known organ specific disease and/or incidental findings confirmed on other scan modality prior to SSTR PET/CT, 3) lack of diagnosis and/or follow up, and 4) results published in proceedings or conference abstracts.
Results: Twenty-one studies, comprising a total of 2906 subjects, were eligible for the analysis. Studies included were retrospective cohort studies on incidental SSTR PET/CT findings in a specific organ (n = 2888, 7/21) or case reports (n = 18, 14/21). A total of 133 subjects had incidental SSTR PET/CT findings. Incidental findings were predominantly seen in the thyroid gland (n = 65), spine (n = 30), brain (n = 26) and breast (n = 6). Seventeen of 133 (13%) incidental findings were malignant on final diagnosis. Incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually.
Conclusion: The most incidental SSTR PET/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET/CT and in the counseling of clinicians.
Luo J, Bahlis N, Chan D, Duggan P, Jimenez-Zepeda V, Lee H Curr Oncol. 2024; 31(12):7445-7458.
PMID: 39727673 PMC: 11674242. DOI: 10.3390/curroncol31120550.
Sjostedt S, Hahn C, Rasmussen A, Oturai P, Cramon P Endocr Connect. 2024; 13(12).
PMID: 39579473 PMC: 11623246. DOI: 10.1530/EC-24-0419.
Lesnikov V, Golovanov I, Nelyubina Y, Aksenova S, Sukhorukov A Nat Commun. 2023; 14(1):7673.
PMID: 37996433 PMC: 10667252. DOI: 10.1038/s41467-023-43530-6.
Johnson F, Hofauer B, Wirth M, Wollenberg B, Stogbauer F, Notohamiprodjo S Cancers (Basel). 2023; 15(15).
PMID: 37568733 PMC: 10417029. DOI: 10.3390/cancers15153917.
Adnan A, Basu S Diagnostics (Basel). 2023; 13(13).
PMID: 37443548 PMC: 10341107. DOI: 10.3390/diagnostics13132154.